HCV

Viral Infection

HCV vaccine in collaboration with CSL Ltd.

This program explores the safety and immunogenicity of HCV vaccine candidates.

Hepatitis C Virus

Hepatitis C is a disease of the liver caused by the hepatitis C virus (HCV). HCV is a major cause of acute hepatitis and chronic liver disease, including cirrhosis and liver cancer. Globally, an estimated 170 million persons are chronically infected with HCV and 3 to 4 million persons are newly infected each year. HCV is spread primarily by direct contact with human blood. The major causes of HCV infection worldwide are use of unscreened blood transfusions, and re-use of needles and syringes that have not been adequately sterilized or from an infected mother to her baby during birth. HCV infection may also impact the course and management of HIV infection. Due to similar ways of infection transmission HIV-infected persons are facing a high risk of concurrent infection with HCV. A treatment or a vaccine for prevention against HCV is currently not available.

Novartis's historically strong involvement in the field of hepatitis research aids our development of a HCV-Vaccine as the companies contribution to further improvement of public health.

HCV vaccine in collaboration with St. Louis University

This program explores the safety and immunogenicity of HCV vaccine candidates.

decrease text sizeincrease text size contact help

About Novartis

About Novartis

We provide medicines to treat and prevent diseases, ease suffering and improve quality of life.

Learn more about our company

News

14 May 2008
Data show Novartis Meningitis B (MenB) vaccine has potential to be first vaccine to provide broad protection to infants against meningococcal B infections. The meningococcal B strain causes 72% of meningococcal disease in Europe and is a major cause of the disease in other regions of the world. Novartis MenB vaccine and Novartis MenveoŽ (MenACWY-CRM) vaccine on track to establish strong portfolio of meningitis vaccines.

06 May 2008
First Phase III, head-to-head data show Menveo may offer greater protection for adolescents compared to Menactra*. Novartis expects Menveo to be first quadrivalent meningococcal vaccine to protect from early infancy through adulthood. More than 8 million infants and adolescents in the US and a significant number of children and travellers globally could benefit from Menveo[1]

>